Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile

Antonio González-Martín, Emilio Alba, Eva Ciruelos, Javier Cortés, Antonio Llombart, Ana Lluch, Raquel Andrés, Isabel Álvarez, José Manuel Aramendía, Francisco Ayala de la Peña, Agustí Barnadas, Norberto Batista, Lourdes Calvo, Elena Galve, Andrés García-Palomo, José Ángel García-Sáenz, Juan de la Haba, Rafael López, Guillermo López-Vivanco, Noelia Martínez-JáñezEduardo Martínez de Dueñas, Arrate Plazaola, Álvaro Rodríguez-Lescure, Manuel Ruiz, Pedro Sánchez-Rovira, Ana Santaballa, Miguel Ángel Seguí, Ignasi Tusquets, Pilar Zamora, Miguel Martín

Producció científica: Contribució a una revistaArticleRecercaAvaluat per experts

9 Cites (Scopus)

Resum

© 2016 Bentham Science Publishers. Around 40% of patients with breast cancer will present with a recurrence of the disease. Chemotherapy is recommended for patients with recurrent hormone-independent or hormone-refractory breast cancer and almost all patients with metastatic breast cancer (MBC) receive chemotherapy during their medical history. Nanoparticle albuminbound (nab)-paclitaxel is a solvent-free, 130-nanometer particle formulation of paclitaxel. Nab-paclitaxel can be administered to all patients for whom the treatment choice is a taxane. In this review, 6 patient profiles for which nabpaclitaxel may be particularly useful are described and analyzed: (i) as first-line treatment of MBC, (ii) as second-line treatment of MBC after oral chemotherapy, (iii) after a standard taxane, (iv) as third-line treatment after a standard taxane and oral chemotherapy, (v) for patients with HER2-positive MBC and (vi) for patients with intolerance to standard taxanes. Nab-paclitaxel is a rational treatment choice for patients with MBC in different settings, as well as for those with prior exposure to a standard taxane.
Idioma originalEnglish
Pàgines (de-a)415-428
RevistaCurrent Cancer Drug Targets
Volum16
Número5
Estat de la publicacióPublicada - 1 de juny 2016

Fingerprint

Navegar pels temes de recerca de 'Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile'. Junts formen un fingerprint únic.

Com citar-ho